NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…
Search results for: vitamin D
RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
Healthy Diet Linked to Lower Hip Fracture Risk in U.S. Women
(Reuters Health)—Eating an overall healthy diet is tied to a lower risk of hip fracture among women over age 50, a U.S. study suggests. Researchers analyzed decades’ worth of dietary and health data for more than 100,000 U.S. men and women. They found that women who scored highest on the American Healthy Eating Index-2010 (AHEI)…
3 Experts Discuss Bone Health
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting Nov. 3–8, experts discussed improving bone health in the U.S., gave tips on bone health disorders in pediatrics and reviewed new translational science findings for joint conservation in early osteonecrosis. E. Michael Lewiecki, MD, director of the New Mexico Clinical Research & Osteoporosis Center in Albuquerque, N.M., called…
Intriguing Patient Cases Presented at the ACR Annual Meeting Thieves Market
SAN DIEGO—At the 2017 Thieves Market, held Nov. 6 at the ACR/ARHP Annual Meeting, rheumatologists from around the world presented patient cases to an audience of colleagues, who then voted via text messaging to choose the cases they felt were most perplexing or intriguing. The winner received a free 2018 Annual Meeting registration, and the…
New Rheumatology Disease Research & Advice
SAN DIEGO—Top researchers gathered for a review course at the start of the 2017 ACR/ARHP Annual Meeting in November to describe new research, their own treatment strategies and new ways of thinking about an array of rheumatic diseases. Here are the highlights: Raynaud’s & Other Digit Problems When a patient walks into your clinic with…
How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease
Anemia is common in patients with systemic rheumatic disease, yet it may not get the attention it deserves. Anemia can result from chronic inflammation, treatment side effects or other disease factors, or it may signal an unrelated condition. Although diagnosis and treatment of anemia are sometimes challenging, clinicians must do their utmost to rigorously investigate…
Rheumatology Case Report: Hand Abnormalities Feature of Fetal Hydantoin Syndrome
Research has shown that anticonvulsants are teratogens and pose a risk for fetal malformations. Meadow was the first to note a possible link between congenital abnormalities and maternal use of anticonvulsive drug in 1968.1 In 1974, Barr et al noted hypoplasia and irregular ossification of the digital distal phalanges with nail dystrophy in children born to…
Undetected Fractures Linked to Back Pain in Older Men
(Reuters Health)—About three in five older men with tiny spinal fractures related to osteoporosis reported new or worsening back pain in a new study. Only about one-quarter of new vertebral fractures are diagnosed by a doctor, the study team writes in their September 7 online report in Journal of Bone and Mineral Research, though the…
Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More
Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 22
- Next Page »